Investigational Product Exposure Section
ICH E3 includes extent of exposure within safety evaluation so reviewers can understand dose, duration, treatment exposure, and related context for interpreting safety findings. Do not confuse exposure with investigational-product accountability, which tracks receipt, storage, dispensing, return, and reconciliation rather than the participant-level amount/duration of treatment received.
An Investigational Product Exposure section summarizes how much study treatment participants actually received so safety findings can be interpreted against dose and duration.
Key details
Important caveats
Scope Boundary
Do not confuse exposure with investigational-product accountability, which tracks receipt, storage, dispensing, return, and reconciliation rather than the participant-level amount/duration of treatment received.
Further guidance
Content
Present the exposure measures relevant to the study—such as duration, dose, cumulative exposure, or treatment groups—using the definitions and summaries expected by the CSR framework.
Purpose
An Investigational Product Exposure section summarizes how much study treatment participants actually received so safety findings can be interpreted against dose and duration.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E3 Structure and Content of Clinical Study Reports (opens in a new tab)U.S. Food and Drug Administration · FDA-hosted ICH E3 guidance defining the structure and content of a core clinical study report